Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PlateletBio
Finance Watch: Arbor, Acrivon, Bit.Bio Close VC Mega-Rounds
Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Platelet BioGenesis, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.